Andy Chen, M.D., Ph.D.

Andy Chen, M.D., Ph.D., is an Associate Professor of Medicine at Oregon Health & Science University. His research focuses on cancer immunotherapy, specifically chimeric antigen receptor (CAR) T-cell therapy for lymphoid malignancies, including follicular lymphoma, Richter transformation, and T-cell lymphomas. His recent work includes multicenter real-world analyses of CAR-T toxicities and outcomes, the 5-year update of the Phase 2 ELARA trial, and investigations into CD5-directed CAR-T therapy. He also studies cellular therapy regimens for older patients with myeloid malignancies. His contributions span clinical trial leadership and consortium-based outcome studies, advancing the safety and efficacy of adoptive cell transplantation.